Revenue reaches KRW 1.5 trillion, up 45.8%
Operating margin rises 4.7 percentage points
"Driven by a higher share of high-margin follow-on products"

Celltrion achieved its highest-ever quarterly revenue and operating profit in the third quarter of this year. Driven by expanded sales of high-margin new products and improvements to its cost structure, operating profit exceeded 500 billion won for the first time since the company was founded.


Celltrion Q3 Operating Profit Soars 70% to Record KRW 510 Billion View original image

Celltrion disclosed preliminary consolidated results on October 12, reporting revenue of 1.5 trillion won and operating profit of 510 billion won for the third quarter of this year. These figures represent increases of 45.8% and 69.2%, respectively, from the same period last year. The operating margin rose by 4.7 percentage points year over year to 34%.


Celltrion has now exceeded its earnings targets for three consecutive quarters. At the beginning of this year, the company set operating profit targets of at least 300 billion won for the first quarter, 400 billion won for the second quarter, and 500 billion won for the third quarter. The company said the results reflect the stable sales of existing products, growth in revenue from higher-margin follow-on products, and the effects of production efficiency improvements and cost reductions.


In Europe, sales grew primarily for Remsima SC, a treatment for autoimmune diseases, and Omlyclo, a treatment for allergic diseases. Omlyclo, which is sold in 26 European countries, recorded a market share of more than 90% in Spain as of July this year. In Denmark, Celltrion expects the product to achieve a market share of at least 98% by the end of the year, supported by wins in national tenders.


In the U.S. market, both existing and follow-on products showed steady growth. As of August, Steqeyma and Yuflyma had market shares of 15% and 11%, respectively. The company's established flagship products, Truxima and Inflectra, maintained shares of 39% and 31%, respectively. Analysts say sales synergies are strengthening as Celltrion expands the direct sales network it built for existing products to include new ones.


Omlyclo, newly launched in the U.S., is expected to provide an additional growth driver in the fourth quarter. Earlier this month, Celltrion launched Omlyclo in the U.S., making it the first omalizumab biosimilar available in the country. Upon launch, it was listed as a preferred drug on the commercial insurance formulary of Optum, one of the three largest pharmacy benefit managers (PBMs) in the U.S. The product is now awaiting reimbursement coverage in the fourth quarter. Expanded tender wins and supply volumes in major European countries are also expected to contribute to earnings growth.



A Celltrion official said, "We will continue to increase the share of high-margin follow-on products and improve costs, while doing our utmost to meet our business plan for the fourth quarter and the full year, supported by the U.S. launch of Omlyclo and expanded supply in Europe."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing